Literature DB >> 11179059

Reciprocal regulation of cGMP-mediated vasorelaxation by soluble and particulate guanylate cyclases.

M B Hussain1, R J MacAllister, A J Hobbs.   

Abstract

Nitric oxide (NO) and atrial natriuretic peptides (ANP) activate soluble (sGC) and particulate guanylate cyclase (pGC), respectively, and play important roles in the maintenance of cardiovascular homeostasis. However, little is known about potential interactions between these two cGMP-generating pathways. Here we demonstrate that sGC and pGC cooperatively regulate cGMP-mediated relaxation in human and murine vascular tissue. In human vessels, the potency of spermine-NONOate (SPER-NO) and ANP was increased after inhibition of endogenous NO synthesis and decreased by prior exposure to glyceryl trinitrate (GTN). Aortas from endothelial NO synthase (eNOS) knockout (KO) mice were more sensitive to ANP than tissues from wild-type (WT) animals. However, in aortas from WT mice, the potency of ANP was increased after pretreatment with NOS or sGC inhibitor. Vessels from eNOS KO animals were less sensitive to ANP after GTN pretreatment, an effect that was reversed in the presence of an sGC inhibitor. cGMP production in response to SPER-NO and ANP was significantly greater in vessels from eNOS KO animals compared with WT animals. This cooperative interaction between NO and ANP may have important implications for human pathophysiologies involving deficiency in either mediator and the clinical use of nitrovasodilators.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11179059     DOI: 10.1152/ajpheart.2001.280.3.H1151

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  16 in total

Review 1.  Cyclic nucleotide-dependent relaxation pathways in vascular smooth muscle.

Authors:  Manuel Morgado; Elisa Cairrão; António José Santos-Silva; Ignacio Verde
Journal:  Cell Mol Life Sci       Date:  2011-09-27       Impact factor: 9.261

Review 2.  Vasopeptidase inhibition and endothelial function in hypertension.

Authors:  L V d'Uscio; T F Lüscher
Journal:  Curr Hypertens Rep       Date:  2001-12       Impact factor: 5.369

3.  Reciprocal regulation of human soluble and particulate guanylate cyclases in vivo.

Authors:  M Madhani; M Okorie; A J Hobbs; R J MacAllister
Journal:  Br J Pharmacol       Date:  2006-10-03       Impact factor: 8.739

4.  Preservation of nitric oxide-induced relaxation of porcine coronary artery: roles of the dimers of soluble guanylyl cyclase, phosphodiesterase type 5, and cGMP-dependent protein kinase.

Authors:  Juan Liu; Zhengju Chen; Liping Ye; Huixia Liu; Dou Dou; Limei Liu; Xiaoxing Yu; Yuansheng Gao
Journal:  Pflugers Arch       Date:  2014-01-12       Impact factor: 3.657

5.  Reciprocal regulation of cyclic GMP content by cyclic GMP-phosphodiesterase and guanylate cyclase in SHR with CsA-induced nephrotoxicity.

Authors:  N Hosogai; J Seki; T Goto
Journal:  Br J Pharmacol       Date:  2001-11       Impact factor: 8.739

6.  Role of the soluble guanylyl cyclase alpha1/alpha2 subunits in the relaxant effect of CO and CORM-2 in murine gastric fundus.

Authors:  Ole De Backer; Ellen Elinck; Patrick Sips; Emmanuel Buys; Peter Brouckaert; Romain A Lefebvre
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-06-18       Impact factor: 3.000

Review 7.  Modulation of cGMP in heart failure: a new therapeutic paradigm.

Authors:  Guido Boerrigter; Harald Lapp; John C Burnett
Journal:  Handb Exp Pharmacol       Date:  2009

8.  Vascular natriuretic peptide receptor-linked particulate guanylate cyclases are modulated by nitric oxide-cyclic GMP signalling.

Authors:  Melanie Madhani; Ramona S Scotland; Raymond J MacAllister; Adrian J Hobbs
Journal:  Br J Pharmacol       Date:  2003-08       Impact factor: 8.739

9.  Synergy between natriuretic peptides and phosphodiesterase 5 inhibitors ameliorates pulmonary arterial hypertension.

Authors:  Reshma S Baliga; Lan Zhao; Melanie Madhani; Belen Lopez-Torondel; Cristina Visintin; David Selwood; Martin R Wilkins; Raymond J MacAllister; Adrian J Hobbs
Journal:  Am J Respir Crit Care Med       Date:  2008-08-08       Impact factor: 21.405

10.  Brain natriuretic peptide in pulmonary arterial hypertension: biomarker and potential therapeutic agent.

Authors:  Brian Casserly; James R Klinger
Journal:  Drug Des Devel Ther       Date:  2009-12-29       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.